TARS
Tarsus Pharmaceuticals, Inc.
Key Financials
Operating Income
$-70969000
↑ 41.1%
Net Income
$-66418000
↑ 42.5%
Revenue
$451.4M
↑ 146.7%
Total Assets
$562.2M
↑ 49.1%
Shareholders' Equity
$343.4M
↑ 53.0%
EPS (Diluted)
$-1.59
↑ 48.2%
Cash & Equivalents
$183.6M
↑ 93.7%
Long-term Debt
$72.4M
↑ 0.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 4 | 3/24/2026 | View on SEC |
| 144 | 3/20/2026 | View on SEC |
| 4 | 3/19/2026 | View on SEC |
| 4 | 3/19/2026 | View on SEC |
| 4 | 3/19/2026 | View on SEC |
| 4 | 3/19/2026 | View on SEC |
| 4 | 3/19/2026 | View on SEC |
| 4 | 3/19/2026 | View on SEC |
| 4 | 3/19/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TARS |
| Company Name | Tarsus Pharmaceuticals, Inc. |
| CIK | 1819790 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (949) 409-9820 |